X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Study Bringing Personalised Immunotherapy Therapies Closer

Content Team by Content Team
24th November 2022
in News, Research & Development

In an effort to advance personalised cancer treatment, researchers have shown that biomarkers alone cannot predict which patients will benefit most from immunotherapy.

Clinicians should comprehend how immune cells and tumours are functioning within a patient rather than relying solely on the presence of related protein levels, based on a study from the Centre for Therapeutic Innovation at the University of Bath (CTI-Bath).

The study was released by the research team and colleagues from Bordeaux in the journal Cancers. Results support a quantitative imaging platform implemented at CTI-Bath that can forecast how an immunotherapy treatment for cancer patients would react.

Typically, cancers hide from the immune system’s ability to recognise them by actively suppressing the body’s natural anti-tumor response. Immune checkpoint inhibitors, a kind of immunotherapy, release the restraints the tumour has placed on the immune system. This triggers the body’s natural defence against cancer, which then kills the tumour.

The research team gathered 15 patients with advanced lung tumours who were receiving radiofrequency ablation (RFA) therapy in order to study the function of these immunological check point regulators in cancer patients. The size of cancers in the other lung may also shrink in some situations when tumours in the first lung are treated with RFA.

Using the immune-FRET molecular imaging tool, which Professor Larijani and colleagues in the UK and the EU developed, researchers examined ratios of the regulators and their targets with how they were interacting. The method can determine how chemicals interact in single cells and tissue samples at the nanoscale.

These interactions have never before been measured in RFA patients, and the results demonstrate that involvement did not correspond with the level of protein present. Therefore, it is unlikely to be appropriate to prescribe based on the amount of proteins present. The results show that readers can get a better picture of what is occurring within a patient by assessing involvement of immune checkpoint interplay, thus more correctly predicting level of immune deficiency and likely response to RFA treatment, rather than simply the levels of the proteins involved, said Professor Banafshe Larijani.

Ultimately, he continued, they hope this can lead to a shift in how immunotherapy is provided to RFA patients so it is tailored to a person.

Previous Post

EMA Forms Quality Control Group To Boost Drug Innovation

Next Post

Pharma Exports of India Grew 138% since 2013-14

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Pharma Exports of India Grew 138% since 2013-14

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In